Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Directorate Appointment

Faron Pharmaceuticals OyAnnouncement

05/05/2026 07:00

Faron Pharmaceuticals Ltd | Company announcement | May 05, 2026 at 09:00:00
EEST

Faron Pharmaceuticals Ltd: Directorate Appointment

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (“Faron”) (AIM: FARN, First North:
FARON), a clinical-stage biopharmaceutical company focused on creating
innovative immunotherapies, is pleased to announce the appointment of Dr.
George Stanley Golumbeski as a Non-executive Director of the Company with
immediate effect.

Dr. Golumbeski currently focuses on supporting the growth of emerging
companies as a partner at DROIA Ventures, a specialized biotech investment
firm. He previously spent nearly ten years as Executive Vice President of
Business Development at Celgene, where he led partnerships with biotechnology
companies aimed at delivering innovative treatments for cancer and chronic
inflammatory diseases. Prior to Celgene, Dr. Golumbeski was Vice President of
Business Development, Licensing and Strategy at Novartis. Prior to Novartis,
he was Vice President of R&D Business Development at Elan and Vice President
of Corporate Development at Schwarz Pharma, where he led CNS acquisitions
worldwide. Dr. Golumbeski earned a Ph.D. in Genetics from the University of
Wisconsin–Madison, completed postdoctoral research in molecular biology at the
University of Colorado Boulder, and received a B.A. in Biology from the
University of Virginia.

The following information regarding the appointment of Dr. Golumbeski is
disclosed under Schedule 2(g) of the AIM Rules for Companies and Nasdaq First
North Growth Market Rulebook.

+---------------------------------------+------------------------------------+
| Current positions, directorships      | Former positions, directorships    |
| and/or partnerships:                  | and/or partnerships (within the    |
|                                       | last five years):                  |
+---------------------------------------+------------------------------------+
| Actio Biosciences, Inc                | Acceleron Pharma, Inc              |
+---------------------------------------+------------------------------------+
| Acumen Pharmaceuticals, Inc           | Ananke Therapeutics, Inc           |
+---------------------------------------+------------------------------------+
| Droia Ventures                        | Vicinitas Therapeutics, Inc        |
+---------------------------------------+------------------------------------+
| Judo Bio, Inc                         | Chroma Medicine, Inc               |
+---------------------------------------+------------------------------------+
| National Audubon Society, Inc         | GRAIL, Inc                         |
+---------------------------------------+------------------------------------+
| Peptone Ltd                           | MorphoSys US, Inc                  |
+---------------------------------------+------------------------------------+
| Shattuck Labs, Inc                    | Mural Oncology PLC                 |
+---------------------------------------+------------------------------------+
| Carrick Therapeutics Limited          | Mural Oncology, Inc                |
+---------------------------------------+------------------------------------+
|                                       | Sage Therapeutics, Inc             |
|                                       |                                    |
+---------------------------------------+------------------------------------+
|                                       | Tizona Therapeutics, Inc           |
|                                       |                                    |
+---------------------------------------+------------------------------------+
|                                       |                                    |
|                                       |                                    |
+---------------------------------------+------------------------------------+

Dr. Golumbeski holds no ordinary shares or options or warrants over ordinary
shares in the Company.

Save as set out above, no further information regarding Dr. Golumbeski is
required to be disclosed pursuant to the AIM Rules for Companies or Nasdaq
First North Growth Market Rulebook.

Tuomo Patsi, Non-Executive Chairman of the Board of Faron Pharmaceuticals,
said: “We are excited to welcome George to our board. His broad experience
will be extremely valuable to Faron as we  continue to progress bexamarilimab
towards next milestones and further develop our long term startegy as a
company.”

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             | +358 50 553 9535 / +44 7 469 766 223 |
|                                     |         kare.laukkanen@irpartners.fi |
| Kare Laukkanen                      |                                      |
|                                     |                                      |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   |                                      |
| (Media)                             |                                      |
| Alyssa Paldo                        |                     +1 847 791-8085  |
|                                     |        alyssa.paldo@finnpartners.com |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        |                                      |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                 +44 (0) 207 213 0880 |
|                                     |                                      |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    |                                      |
| (Certified Adviser on Nasdaq First  |                                      |
| North)                              |                                      |
| Juha Karttunen                      |                  +358 (0)40 555 4727 |
| Jukka Järvelä                       |                  +358 (0)50 553 8990 |
+-------------------------------------+--------------------------------------+

About Faron Pharmaceuticals Ltd.
Faron (AIM: FARN, First North: FARON) is a clinical-stage biopharmaceutical
company developing novel treatments for medical conditions with significant
unmet needs. The Company's pipeline is built on its scientific understanding
of the regulation of the immune system in cancer.

About Bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes
by targeting myeloid cell function. It binds to Clever-1, a receptor on
immunosuppressive macrophages that helps cancer evade the immune system. By
targeting Clever-1, bexmarilimab reprograms the tumor microenvironment to
ignite a potent anti-tumor immune response